Today at the ISSCR 2026 Annual Meeting, Jeanne Loring, Ph.D., Scripps Research, USA, will present interim clinical findings from the first Phase 1/2a trial using autologous induced pluripotent stem cell (iPSC)-derived dopamine neuron precursor cells, along with the novel quality control tools developed to manufacture these individualized therapies.
Parkinson's disease is a progressive neurological disorder caused by the gradual loss of dopamine-producing nerve cells in the brain. As dopamine levels decline, people develop symptoms such as tremor, stiffness, slowed movement, and balance problems. While current medications can temporarily improve symptoms, they do not stop the disease from progressing or replace the neurons that have been lost.
The study, presented at ISSCR 2026 , is sponsored by Aspen Neuroscience, Inc, USA and is using an approach in which dopamine neuron precursor cells are generated from each patient's own cells. Because every patient's cells are unique, the team developed new genomic quality control methods to ensure the manufactured cells are suitable for transplantation. Using whole genome sequencing throughout the manufacturing process, the researchers established a "fail-fast" strategy designed to identify unwanted genetic changes that can arise as iPSCs are expanded and differentiated.
The presentation will describe these quality control tools for autologous manufacturing together with positive interim findings from patients one year after receiving transplants of their own cells.
"The greatest challenge for autologous cell therapy has been developing reliable methods to qualify every patient's cells for treatment," said Jeanne Loring, Ph.D., Scripps Research, USA. "We developed genomic analysis approaches that address cell line heterogeneity and identify mutations that can arise as iPSCs divide, helping establish a rigorous framework for manufacturing personalized therapies."
The trial addresses an important unmet need for people with sporadic Parkinson's disease. While several clinical studies are evaluating stem cell-derived dopamine neurons, this is the first Phase 1/2a trial using autologous iPSC-derived dopamine neuron precursors transplanted into the region of the brain where dopamine neuron input has been lost.
Interim results have been reported for eight patients with mild to moderate Parkinson's disease who remained responsive to L-DOPA treatment and were evaluated 12 months after transplantation.
"We've known for decades that transplanted young dopamine neurons can reverse Parkinson's disease symptoms when the appropriate cells are used," said Loring. "If these findings continue to hold over time, we hope to see meaningful improvements in quality of life that continue to increase as the transplanted cells mature."
While the results provide important proof of concept for the approach, Loring notes that additional questions remain, including determining the optimal therapeutic dose.
"I believe these findings are an important milestone because they provide proof of concept for both the safety and potential efficacy of personalized stem cell therapy," she said. "I'm excited to share these data with the ISSCR community and discuss how far the field has advanced toward translating autologous iPSC technology into clinical therapies."
To learn more about ISSCR 2026 visit www.isscr2026.org
